Pneumococcal, influenza and herpes zoster infections cause significant morbidity and mortality in the aging population. Effective vaccines are available in Canada to prevent and minimize illnesses caused by these infections. The purpose of this review is to provide an overview of the epidemiology of pneumococcal, influenza and herpes zoster infections in older adults, as well as available vaccines and recommended immunization schedules. In addition, the benefits of these vaccines on patient outcomes and the role of pharmacists in improving immunization rates are highlighted.
A literature review was conducted to examine the clinical outcomes related to the use of pneumococcal, influenza and herpes zoster vaccines in adults 65 years and older. All 3 vaccines are beneficial in reducing complications of these infections and are well tolerated in older adults. Studies have shown that the uptake of these vaccines remains suboptimal and the burden of illness caused by these infections continues to affect the quality of life of older adults. Pharmacists are well positioned to screen seniors for vaccine indications during routine assessments, as well as provide education to improve patient awareness, vaccine uptake and health outcomes in older adults.
KovaiouRDGrubeckLoebenstein B. Age-associated changes within CD4+ T cells. Immunol Lett2006;107(1):8–14.
3.
ThompsonWWShayDKWeintraubE. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA2003;289(2):179–86.
4.
StuartBDavidoffALloydJ. Does influenza vaccination of older adult Medicare beneficiaries lower treatment costs for acute and chronic respiratory disease?Am J Geriatr Pharmacother2010;8(3):201–14.
5.
Alberta College of Pharmacy. Guidelines and criteria for injection and immunization continuing education programs for Alberta pharmacists. 2007. Available: https://pharmacists.ab.ca/nCollege/resource.aspx?id=6054 (accessed July 18, 2010).
MiazgaEJBiesboerANHayneyMS. Updated recommendations for the use of pneumococcal polysaccharide vaccine. J Am Pharm Assoc2010;50(2):321–23.
10.
Vila-CórcolesA. Vaccinate your child and save its grandparents from a heart attack? Current perspectives in antipneumococcal vaccination. J Intern Med2009;266(5):432–44.
11.
Statistics Canada. Deaths and mortality rate, by selected grouped causes, age group and sex, Canada, annual. Available: http://cansim2.statcan.gc.ca/cgi-win/cnsmcgi.pgm (accessed November 16, 2010).
12.
Preventing pneumococcal disease: a Canadian consensus conference. Can Commun Dis Rep1999;25(4):25–35.
13.
Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep1997;46(RR-8):1–24.
14.
Environics Research Group (prepared for Public Health Agency of Canada). Canadian adult national immunization coverage (adult NICS) survey — 2006: final report. Available: http://resources.cpha.ca/CCIAP/data/544e.pdf (accessed July 19, 2010).
15.
An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on recommended use of pneumococcal conjugate vaccine. Can Commun Dis Rep2002;28(ACS-2):1–32.
16.
Public Health Agency of Canada. Canadian immunization guide. Seventh edition.Ottawa (ON): Public Health Agency of Canada; 2006:209–20, 267–76.
17.
Vila-CórcolesAOchoa-GondarOHospitalI. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis2006;43(7):860–8.
18.
JacksonLANeuzilKMYuO. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med2003;348(18):1747–55.
19.
HedlundJChristensonBLundberghPOrtqvistA. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up. Vaccine2003;21(25–26):3906–11.
20.
HonkanenPOKeistinenTMiettinenL. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine1999;17(20–21):2493–500.
21.
MaruyamaTTaguchiONiedermanMS. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ2010;340:1004.
22.
KoivulaIStenMLeinonenMMakelaPH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med1997;103 (4):281–90.
23.
ButlerJCBreimanRFCampbellJF. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA1993;270(15): 1826–31.
24.
OrtqvistAHedlundJBurmanLA. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet1998;351(9100):399–403.
25.
FismanDNAbrutynESpaudeKA. Prior pneumococcal vaccination is associated with reduced death, complications and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis2006;42(8): 1093–101.
26.
AlfagemeIVazquezRReyesN. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax2006;61(3):189–95.
27.
MooneyJDWeirAMcMenaminJ. The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. BMC Infect Dis2008;8:53.
28.
DominguezASallerasLFedsonDS. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study. Clin Infect Dis2005;40(9): 1250–7.
29.
AndrewsRMCounahanMLHoggGGMcIntyrePB. Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia. Vaccine2004;23(2): 132–8.
30.
BeninALO'BrienKLWattJP. Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults. J Infect Dis2003;188(1):81–9.
31.
CookIFPondDHartelG. Comparative reactogenicity and immunogenicity of 23-valent pneumococcal vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine2007;25(25):4767–74.
32.
FioreAEShayDKBroderK. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep2009;58(RR-8).
An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on seasonal trivalent inactivated influenza vaccine (TIV) for 2009–2010. Can Commun Dis Rep2009;35(ACS-6):1–41. Available: www.phac-aspc.gc.ca/publicat/ccdr-rmtc/09vol35/acs-dcc-6/index-eng.php (accessed July 10, 2010).
36.
CrocettiEArnianiSBordoniF. Effectiveness of influenza vaccination in the elderly in a community in Italy. Eur J Epidemiol2001;17(2):163–8.
37.
De VilliersPJSteeleADHiemstraLA. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine2009;28(1):228–34.
38.
de DiegoCVila-CorcolesAOchoaO. Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease. Eur Heart J2009;30(2):209–16.
39.
NordinJMulloolyJPobleteS. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York and Oregon: data from 3 health plans. J Infect Dis2001;184(6):665–70.
40.
NicholKLNordinJMulloolyJ. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med2003;348(14):1322–32.
41.
HaraMSakamotoTTanakaK. Influenza vaccine effectiveness among elderly persons living in the community during the 2003–2004 season. Vaccine2008;26(50):6477–80.
42.
VoordouwBCvan der LindenPDSimonianS. Influenza vaccination in community-dwelling elderly: impact on mortality and influenza-associated morbidity. Arch Intern Med2003;163(9):1089–94.
43.
SpaudeKAAbrutynEKirchnerC. Influenza vaccination and risk of mortality among adults hospitalized with community-acquired pneumonia. Arch Intern Med2007;167(1):53–9.
44.
MontoASHornbuckleKOhmitSE. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol2001;154(2):155–60.
45.
Looijmans-Van den AkkerIVerheijTJBuskensE. Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients. Diabetes Care2006;29(8):1771–6.
46.
VoordouwACSturkenboomMCDielemanJP. Annual revaccination against influenza and mortality risk in community-dwelling elderly persons. JAMA2004;292(17):2089–95.
47.
GroenwoldRHHoesAWHakE. Impact of influenza vaccination on mortality risk among the elderly. Eur Resp J2009;34(1):56–62.
48.
Puig-BarberaJDiez-DomingoJVareaAB. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine2007;25(42):7313–21.
49.
FedsonDSWajdaANicolJP. Clinical effectiveness of influenza vaccination in Manitoba. JAMA1993;270(16):1956–61.
50.
WangCSWangSTChouP. Efficacy and cost-effectiveness of influenza vaccination of the elderly in a densely populated and unvaccinated community. Vaccine2002;20(19–20):2494–9.
51.
GovaertTMThijsCTMasurelN. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA1994;272(21):1661–5.
52.
WangCSWangSTLaiCT. Impact of influenza vaccination on major cause-specific mortality. Vaccine2007;25(7):1196–203.
53.
MangtaniPCumberlandPHodgsonCR. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. J Infect Dis2004;190(1):1–10.
54.
BrissonMEdmundsWJLawB. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect2001;127(2):305–14.
55.
OxmanMNLevinMJJohnsonGR. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med2005;352(22):2271–84.
56.
BettsRF. Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia. J Am Acad Dermatol2007;57(6 Suppl):S143–7.
57.
An Advisory Committee Statement (ACS). National Advisory Committee on Immunization. Statement on the recommended use of herpes zoster vaccine. Can Commun Dis Rep2010;36(ACS-1):1–19. Available: www.phac-aspc.gc.ca/publicat/ccdr-rmtc/10vol36/acs-1/index-eng.php (accessed July 27, 2010).
MacaladadNMarcanoTGuzmanM. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine2007;25(11):2139–44.
60.
LevinMJOxmanMNZhangJH. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis2008;197(6):825–35.
61.
TrannoyEBergerRHolländerG. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine2000;18(16):1700–6.
62.
SimberkoffMSArbeitRDJohnsonGR. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med2010;152(9):545–54.
63.
CohenJI. Strategies for herpes zoster vaccination of immunocompromised patients. J Infect Dis2008;197(Suppl 2):S237–41.
64.
Van AmburghJAWaiteNMHobsonEHMigdenH. Improved influenza vaccination rates in a rural population as a result of a pharmacist-managed immunization campaign. Pharmacotherapy2001;21(9):1115–22.
65.
SteyerTERagucciKRPearsonWSMainousAG3rd. The role of pharmacists in the delivery of influenza vaccinations. Vaccine2004;22(8):1001–6.
